Acneiform rash induced by EGFR inhibitors: review of the literature and new insights by Fabbrocini, Gabriella et al.
E-Mail karger@karger.com
 Review Article 
 Skin Appendage Disord 2015;1:31–37 
 DOI: 10.1159/000371821 
 Acneiform Rash Induced by EGFR 
Inhibitors: Review of the Literature and 
New Insights 
 Gabriella Fabbrocini    Luigia Panariello    Gemma Caro    Sara Cacciapuoti 
 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II,  Naples , Italy
 
 Introduction 
 Acneiform rash is the most common side effect of 
epidermal growth factor receptor (EGFR) inhibitors 
(EGFRis). EGFR belongs to a family (ErbB) of tyrosine 
kinase receptors which regulate tumor cell differentia-
tion, survival, and proliferation. EGFR can be inhibited 
by the monoclonal antibodies cetuximab (Erbitux ® ) and 
panitumumab (Vectibix ® ), and by the small molecule ty-
rosine kinase inhibitors erlotinib (Tarceva ® ) and gefi-
tinib (Iressa ® ). EGFR is expressed in many different cell 
types in normal tissues, such as epithelial tissue, skin, hair 
follicles, and the gastrointestinal tract, and during treat-
ment with EGFRis cutaneous adverse events occur in 
about 65–90% of patients. This condition can affect the 
quality of life of these patients and can sometimes lead to 
a discontinuation of the antineoplastic therapy  [1] . The 
most common cutaneous side effect is a dose-dependent 
follicular papulopustular (acneiform) eruption on the 
face, scalp, chest, and upper back ( fig. 1 ). Acneiform rash 
is a dose-dependent skin drug reaction, which usually de-
velops in the first 1–2 weeks, peaks at 3–4 weeks on ther-
apy, and its intensity decreases after 2 weeks but can often 
persist over some months. It is not well known why 
monoclonal antibodies are the most frequent trigger of 
acneiform rash  [2, 3] . This skin reaction is defined ‘acne-
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iform’ rash because the lesions, such as papules, nodules, 
and pustules, look like acne, but in these patients, come-
dones, which are a distinguishing factor of acne, are nev-
er present. Acneiform rash can be distinguished from 
acne vulgaris by the monotonous lesion morphology. 
Several recent prospective studies have addressed and 
evaluated different therapies to mitigate or reduce the se-
verity of EGFRis-associated skin rash  [4–6] . With this 
aim, we have established a dermocosmetological outpa-
tient clinic for cancer patients at the Department of Clin-
ical Medicine and Surgery, University of Naples Federico 
II  [4] in collaboration with the Department of Dermatol-
ogy and Cutaneous Surgery, Miller School of Medicine, 
University of Miami.
 An interdisciplinary network of physicians can im-
prove the quality of life of the cancer patients, focusing on 
such important aspects as dermocosmetological skin 
care, but also on the evaluation of new therapeutic and 
diagnostic algorithms in order to make further progress 
in the field of prevention. In this review, we summarize 
the state of the art of the epidemiology, pathogenesis, and 
treatment of EGFRis acneiform rash, and we describe our 
outpatient clinical experience.
 Epidemiology 
 Papulopustular rash is the most common cutaneous 
adverse event during EGFRis therapy; it has been report-
ed to occur in 50–100% of patients  [7] .
 When its incidence is analyzed in relation to a single 
drug, it is observed in 24–62% of patients on gefitinib, in 
49–67% of patients on erlotinib, and in 75–91% of pa-
tients on cetuximab  [8] .
 Acneiform rash can affect the quality of life of these 
patients, but it also seems to be associated with a good 
antitumor activity (although not all literature reports 
agree  [9] ), and it can be used as a biomarker for prognosis 
in patients receiving EGFRis  [7–15] .
 Pathogenesis 
 The pathogenesis of EGFRis-induced skin rash is not 
well clarified. Nevertheless, some modifications have 
been identified; in particular the inhibition of EGFR ty-
rosine kinase activity seems to be determinant  [15] .
 Lichtenberger et al.  [16] showed that EGFR is ex-
pressed in the basal layer of the epidermis. In papulopus-
tular rash, the main pathogenetic target is the keratino-
cyte and not the cutaneous adnexa. Indeed, the EGFR sig-
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 Fig. 1. Pathogenesis of inflammatory cell 
infiltration occurring in the EGFRis-in-
duced papulopustular rash. 
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nal in the epidermal keratinocytes plays a crucial role in 
several cell activities, such as inflammation, barrier func-
tion, and innate host defense.
 Obviously, EGFRis inhibit both EGFR overexpressed 
in tumor cells and the one expressed in normal cells of 
the epidermis  [16] . In this way, the inhibition of EGFR 
in keratinocytes induces apoptosis, arrests cell growth, 
reduces cell migration, and increases cell adhesivity and 
cell differentiation. All these processes induce keratino-
cytes to release inflammatory chemokines [chemokine 
(C-C motif) ligand 2 (CCL2), chemokine (C-C motif) 
ligand 5 (CCL5), and C-X-C motif chemokine 10 
(CXCL10)/interferon γ-inducible protein 10 (IP-10)]. 
EGFR inhibition is also associated with a reduction of C-
X-C motif chemokine 8 (CXCL8) expression. Conse-
quently, an inflammatory cell infiltration occurs ( fig. 1 ). 
These modifications in the skin lead to the typical cuta-
neous manifestation described above  [15] . In particular, 
the arrest of growth, the migration of keratinocytes, and 
inflammation cause xerosis and papulopustular acne-
iform rash  [16] .
 Histology 
 Histologically, two major patterns of reaction have 
been described: (1) hyperkeratotic or ectatic follicular in-
fundibula surrounded by a superficial dermal inflamma-
tory cell infiltrate, particularly in the upper portion of the 
hair follicle, and (2) neutrophilic suppurative folliculitis 
with rupture of the epithelial lining  [12] . No changes in 
dermal capillaries, eccrine glands or sebaceous glands are 
reported. Microbiological stains and cultures have dem-
onstrated the absence of infection, confirming that this is 
a sterile process.
 These histopathological findings underline the differ-
ent characteristics of papulopustular rash and acne vul-
garis, which is characterized by sebaceous gland hyper-
trophy, comedo development, and inflammatory infil-
trate associated with colonization by  Propionibacterium 
acnes  [14] .
 Clinical Aspects 
 EGFRis-induced rash is an early event: it can occur be-
tween 2 days and 6 weeks after the first drug administra-
tion, but it usually develops within the first 2 weeks  [10] .
 Clinically, the rash is characterized by tender erythem-
atous papules, which after a few days evolve into pustules 
and then into crusts. It affects skin areas with a high den-
sity of sebaceous glands (scalp, face, upper chest, and 
back); however, less commonly, it can involve the extrem-
ities, lower back, and the abdomen ( fig. 2 ,  3 ).
 Lesions can be painful and itching. In some cases, fol-
liculitis may extend to the whole body surface, always 
sparing the palms, soles, and mucosa  [11] . Even if the mu-
cosa is not involved by the rash, they could be interested 
by xerosis (xerophthalmia, xerostomia) with an incidence 
varying from 12 to 35%, and this is considered one of the 
most important aspects that influence a patient’s quality 
of life  [16] .
 Fig. 2. Papulopustular rash on the trunk of 
a patient affected by lung cancer and treat-
ed with erlotinib. 
 Fig. 3. Papulopustular rash on the face of a 
patient affected by lung cancer and treated 
with erlotinib. 
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 Although this rash has been referred to as ‘acneiform’ 
and ‘acne-like’, it has clinically, etiologically, and histo-
pathologically different characteristics compared to acne 
 [12] . In fact, in contrast to acne, EGFRis-associated rash 
is predominantly pustular and not associated with com-
edones (blackheads or whiteheads).
 There are several proposed score systems to grade the 
severity of EGFRis-associated rash. The most commonly 
used is the US Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.0, which recognizes 5 
grades ( table 1 )  [7] .
 Complications 
 Among the complications of acneiform rash, impetig-
inization is very frequent, and it can be clinically confused 
with a severe grade of papulopustular rash. A bacterial 
overlapping should be suspected when a sudden worsen-
ing of the rash (more polymorphous lesions and charac-
teristic honey-colored crust) and different symptoms oc-
cur. The major bacterium responsible for the impetigini-
zation is  Staphylococcus aureus, especially in patients with 
nasal carriage and mid-face involvement  [11] .
 Therapy 
 In the recent literature, few studies on the manage-
ment of cutaneous side effects of EGFRis can be found. 
However, different therapeutic strategies have been pro-
posed for the effective management of dermatological ad-
verse events associated with EGFRis therapy. With the 
increasing rate of EGFRis therapy, a higher proportion of 
patients develop papulopustular exanthemas and other 
cutaneous side effects. This led a panel of German derma-
tologists to draw up recommendations on the manage-
ment of these cutaneous side effects. These recommenda-
tions provide a 3-step guideline that ranges from general 
measures/preventive measures (step 1) to measures that 
can be performed by the primary treating physician (step 
2) and to advanced therapy by an experienced dermatolo-
gist (step 3). Step 1 includes general preventive measures: 
before starting treatment, patients should be informed of 
the various cutaneous side effects and the typical mani-
festation. At the beginning of the EGFRis therapy, pa-
tients should be advised to moisturize dry areas of their 
 Table 1.  NCI-CTCAE version 4.0 grading scale of skin and subcutaneous tissue disorders
EGFRis-associated rash
 Grade 1 Papules and/or pustules covering <10% of the BSA associated or not associated with symptoms of 
pruritis or tenderness
Grade 2 Papules and/or pustules covering 10 – 30% of the BSA associated or not associated with symptoms
of pruritis or tenderness; psychosocial impact; limiting instrumental ADL
 Grade 3 Papules and/or pustules covering >30% of the BSA associated or not associated with pruritis or
tenderness; limiting self-care ADL, associated with local superinfection (oral antibiotics indicated)
Grade 4 Covering any percentage of the BSA associated or not with pruritis or tenderness; associated with 
severe superinfection (intravenous antibiotics indicated); life-threatening consequences 
Grade 5 Death
 BSA = Body surface area; ADL = activity of daily living.
 Table 2. General preventive measures to adopt before EGFRis 
treatment to reduce follicular rash severity
Avoidance of skin contact with skin irritants such as solvents, 
disinfectants, polishes
Use of mild bath or shower oils or syndets (no soap)
Use of moisturizers and/or urea-containing skin care products 
(ointment, cream) without fragrances or other skin irritants (no 
lotion or gel)
Avoidance of activities which mechanically stress the skin (e.g. 
garden work, carrying heavy objects, and hot hair drying)
Avoidance of frequent hand washing, daily, long showers or 
frequent, long baths
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body twice a day. For this purpose, a thick alcohol-free 
emollient is recommended. Patients should also be ad-
vised to minimize their exposure to sunlight because rash 
may be more severe in sun-exposed areas of the skin  [17, 
18] . In this phase, preexisting skin diseases such as rosa-
cea or seborrheic dermatitis should be diagnosed and an 
adequate therapy prescribed if needed. Other preventive 
measures are summarized in  table 2 .
 Some authors also proposed the use of some topical 
agents in this phase with the aim of reducing follicular 
rash severity. Tomková et al.  [19] assessed the possible ef-
fect of topical phytomenadione (vitamin K 1 ) pretreat-
ment on diminishing the extent and severity of acne-like 
follicular rash associated with EGFRis therapy. The ratio-
nale for this study was the observation that menadione 
stabilizes the phosphorylation of EGFR, and it can be use-
ful for a targeted prophylaxis of EGFRis-induced cutane-
ous lesions. However, generally, topical (and eventually 
systemic) agents are prescribed when rash appears (step 
2). In these cases, the following interventions are suggest-
ed based on the severity of the reaction:
 (1) Mild toxicities: patients may not require any form 
of intervention; however, it may be appropriate to treat 
some mild toxicities with topical hydrocortisone (1 or 
2.5% cream) or clindamycin (1% gel).
 (2) Moderate toxicities: the treatment used includes 
hydrocortisone (2.5% cream), clindamycin (1% gel), or 
pimecrolimus (1% cream) with the addition of either 
doxycycline (100 mg, p.o. bid) or minocycline (100 mg, 
p.o. bid)  [20, 21] .
 With these measures, usually 80% of the rash manifesta-
tions can be controlled well. Both in mild and in moderate 
toxicities, the EGFRis dosage should not be modified. In 
case of an inadequate response, the patient needs a step 3 
therapy for the management of severe toxicities: the con-
comitant intervention is the same as for moderate toxici-
ties – i.e., hydrocortisone (2.5% cream), clindamycin (1% 
gel), or pimecrolimus (1% cream), with the addition of ei-
ther doxycycline (100 mg, p.o. bid) or minocycline (100 
mg, p.o. bid) – but with the addition of methylpredniso-
lone dose pack. Microbial diagnostics in order to recognize 
and early treat a possible bacterial superinfection is neces-
sary. If toxicities are not reduced after 2–4 weeks, despite 
treatment, then the interruption of EGFRis therapy is rec-
ommended in accordance with prescribing information. 
Sometimes, only a reduction in EGFRis dose might be nec-
essary. In  table 3 , we report some additional recommenda-
tions to increase therapy response and its maintenance.
 From October 2010 through July 2014, 350 patients 
were referred to our dermatological outpatient clinic for 
 Table 3. Additional recommendations to increase therapy response and its maintenance
Recommendations Aim
Maintain topical or systemic therapy even if EGFRis 
therapy is decreased or is interrupted
To avoid skin toxicity recurrence
Do not use topical corticosteroids for >14 days
without interruption and give preference to pulse 
therapy application of topical corticosteroids (e.g. 14 
days on treatment, then 7 days off treatment)
To avoid dermal toxicity and reduce the risk for
bacterial or viral superinfection
Prescribe systemic therapy when papulopustular 
exanthema develops on the scalp
To offer an effective protection from the development 
of a severe papulopustular exanthema
Perform an antibiogram in all cases of resistant and 
severe papulopustular rash
To individuate and treat early bacterial superinfection
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cancer patients at the Section of Dermatology, Depart-
ment of Clinical Medicine and Surgery, University of Na-
ples Federico II ( fig. 4 ). The patients’ data were registered 
using a software set up specifically to record general in-
formation, tumor grading, type of chemotherapy, and 
skin manifestations.
 Patients were between 19 and 81 years old (mean age, 
56 years); 124 were men and 226 women. Among them, 
120 patients were treated with EGFRis (cetuximab, erlo-
tinib, lapatinib, gefitinib, and panitumumab). This clus-
ter consisted of 38 men and 82 women aged between 44 
and 81 years (mean age, 63 years); 52.17% of them were 
affected by lung cancer, 17.39% by colon cancer, 8.7% by 
breast cancer, 8.7% by head and neck cancer, and 4.34% 
by thymus cancer.
 80% of the patients treated with EGFRis developed a 
papulopustular rash. The severity of the rash was evalu-
ated by CTCAE version 4.03.
 According to the data reported in the literature, the 
papulopustular rash usually occurred within 2–3 weeks 
after the administration of the drug and reached the up-
per level after 1 month; this was also the case in our sam-
ple. Skin lesions started as erythematous follicular pap-
ules, but after a few days they evolved into pustules and 
then into crusts.
 The lesions were above all localized on the face, neck, 
and retroauricular area, scalp and upper trunk, but the 
abdomen, arms, and legs were also involved. The majority 
of our patients developed a mild to moderate rash (grades 
1 and 2), but 4 patients developed a severe rash (grade 3).
 According to our experience, we developed a thera-
peutic protocol that recommends the application once or 
twice a day (depending on the severity of the rash) of a 
mixture of clindamycin 1% gel and gentamicin 0.1% un-
guent on the affected area. This leads to a complete reso-
lution of the rash within 2 weeks for mild to moderate 
rash ( fig. 5 ,  6 ).
 For more severe rash, this topical application might 
not be sufficient. In these cases, we usually prescribe 
prednisone 12.5–25 mg/day for a week, progressively de-
creasing the dose. In 2 patients affected by lung cancer 
and treated with erlotinib, we prescribed doxycycline 40 
mg bid for a month, however, obtaining excellent results 
only in 1 case. We decided to administer a lower dose of 
doxycycline in order to only benefit from the anti-inflam-
matory effect of this drug without its antibiotic action, 
with the aim to reduce the risk of antibiotic resistance and 
intestinal side effects  [21, 22] .
 Besides the pharmacological treatment, it is necessary 
to pay attention to the dermocosmetological care of the 
patients treated with EGFRis. They should be advised to 
use an alcohol-free highly occlusive moisturizing agent 
and lukewarm water, to avoid prolonged, hot showers, as 
well as to use a broad-spectrum sunscreen.
 Fig. 6. Papulopustular rash on the face before and after topical 
treatment. 
 Fig. 5. Papulopustular rash before and after 
topical therapy. 
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 To cover grade 1 and 2 rash, a nonocclusive makeup 
could be used, which is usually tolerated well by patients. 
In order to protect the stratum corneum barrier, cosmet-
ic formulations containing fatty acids and ceramides are 
recommended.
 Conclusions 
 The increasing use of new targeted therapy for several 
oncological diseases can be determinant for the patients’ 
survival. Nevertheless, it can cause mild to moderate skin 
manifestations. Even if they might be considered as a bio-
marker for a good outcome, they highly affect the quality 
of life of these patients.
 For these reasons, it is important for dermatologists to 
recognize the symptoms and to cure the manifestations 
in order to avoid the discontinuation of the patients’ can-
cer treatment.
 With this aim, a strong collaboration among derma-
tologists and between dermatologists and oncologists will 
be necessary to create guidelines for the diagnosis and 
therapy of EGFRis-induced cutaneous side effects.
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